CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study |
| |
Authors: | T. J. Barber A. Imaz M. Boffito J. Niubó A. Pozniak R. Fortuny J. Alonso N. Davies S. Mandalia D. Podzamczer B. Gazzard |
| |
Affiliation: | 1.Chelsea and Westminster NHS Foundation Trust and St Stephen’s AIDS Trust, 4th Floor, St Stephen’s Centre, Chelsea and Westminster Hospital,London,UK;2.Imperial College London,London,UK;3.Bellvitge University Hospital,Barcelona,Spain;4.Hospital Universitari Vall d’Hebron,Barcelona,Spain |
| |
Abstract: | CINAMMON is a phase IV, open-label, single-arm, pilot study assessing maraviroc (MVC) in the central nervous system (CNS) when added to darunavir/ritonavir monotherapy (DRV/r) in virologically suppressed HIV-infected subjects. CCR5 tropic participants on DRV/r were recruited. Participants remained on DRV/r for 12 week (w) (control phase). MVC 150 mg qd was added w12–w36 (intervention phase). Lumbar puncture (LP) and neurocognitive function (Cogstate) examinations scheduled at baseline, w12 and w36; MRI before w12, again at w36. Primary endpoint was CSF inflammatory marker changes during intervention phase. Secondary endpoints included changes in NC function and MRI parameters. CSF/plasma DRV/r concentrations measured at w12 and w36, MVC at w36. Nineteen patients recruited, 15 completed (17M, 2F). Dropouts: headache (2), knee problem (could not attend, 1), personal reasons (1). Mean age (range) 45.4 years (27.2–65.1), 13/19 white, 10/19 MSM. No changes in selected CSF markers were seen w12–w36. Overall NC function did not improve w12–w36: total age adjusted z score improved by 0.27 (weighted paired t test; p?=?0.11); for executive function only, age adjusted z score improved by 0.54 (p?=?0.03). MRI brain parameters unchanged. DRV plasma:CSF concentration ratio unchanged between w12 (132) and w36 (112; p?=?0.577, Wilcoxon signed-rank). MVC plasma:CSF concentration ratio was 35 at w36. No changes in neuroinflammatory markers seen. In this small study, addition of 24w MVC 150 mg qd to stable DRV/r monotherapy showed possible improvement in executive function with no global NC effect. Learning effect cannot be excluded. This effect should be further evaluated. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|